JP2000503849A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2000503849A5 JP2000503849A5 JP1997527123A JP52712397A JP2000503849A5 JP 2000503849 A5 JP2000503849 A5 JP 2000503849A5 JP 1997527123 A JP1997527123 A JP 1997527123A JP 52712397 A JP52712397 A JP 52712397A JP 2000503849 A5 JP2000503849 A5 JP 2000503849A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59300996A | 1996-01-29 | 1996-01-29 | |
| US08/593,009 | 1996-01-29 | ||
| PCT/US1997/001609 WO1997027319A1 (en) | 1996-01-29 | 1997-01-29 | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2000503849A JP2000503849A (ja) | 2000-04-04 |
| JP2000503849A5 true JP2000503849A5 (cg-RX-API-DMAC7.html) | 2004-11-11 |
| JP4183749B2 JP4183749B2 (ja) | 2008-11-19 |
Family
ID=24372979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52712397A Expired - Fee Related JP4183749B2 (ja) | 1996-01-29 | 1997-01-29 | 抗ウィルス剤感受性及び耐性を決定するための組成物及び方法並びに抗ウィルス剤のスクリーニング |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP0852626B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4183749B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR100537153B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1263867C (cg-RX-API-DMAC7.html) |
| AP (1) | AP9801360A0 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE447621T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU732255B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2216126C (cg-RX-API-DMAC7.html) |
| DE (2) | DE69711584T2 (cg-RX-API-DMAC7.html) |
| EA (1) | EA005426B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2175355T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUP9900388A3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL125464A (cg-RX-API-DMAC7.html) |
| NO (1) | NO983421L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ331376A (cg-RX-API-DMAC7.html) |
| PL (1) | PL328068A1 (cg-RX-API-DMAC7.html) |
| RO (1) | RO118887B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1997027319A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2123065T3 (es) | 1992-08-25 | 1999-01-01 | Searle & Co | Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas. |
| KR100495690B1 (ko) | 1996-01-26 | 2005-11-08 | 비르코 비브이비에이 | 인체 hiv 계통의 표현형적 약제 감수성에 기초한 하나 이상의 최적한 hiv 저해제를 선발하는 방법 |
| US6242187B1 (en) | 1996-01-29 | 2001-06-05 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
| CA2298102A1 (en) * | 1997-07-30 | 1999-02-11 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
| WO1999051776A1 (en) * | 1998-04-07 | 1999-10-14 | Southern Research Institute | High-throughput method for screening for antiviral activity |
| US7037644B1 (en) | 1998-05-26 | 2006-05-02 | Virologic, Inc. | Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS |
| NZ508834A (en) * | 1998-05-26 | 2004-06-25 | Virologic Inc | Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy |
| US20030148307A1 (en) | 1998-06-19 | 2003-08-07 | Department Of Health & Human Services, C/O Centers Of Disease Control And Prevention | Method and kit for detecting resistance to antiviral drugs |
| US6787126B1 (en) | 1998-06-19 | 2004-09-07 | The United States Of America As Represented By The Department Of Health And Human Services | Method and kit for detecting resistance to antiviral drugs |
| CA2331260C (en) * | 1998-06-19 | 2008-03-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method and kit for detecting resistance to antiviral drugs |
| BR9912209A (pt) * | 1998-06-24 | 2002-11-05 | Virologic Inc | Recursos e métodos para monitoração de terapia anti-retroviral inibidora de transcriptase reversa de nucleosìdeo e guia de decisões terapêuticas no tratamento de hiv/aids |
| ES2246859T3 (es) | 1999-05-28 | 2006-03-01 | Virco Bvba | Nuevos perfiles mutacionales en la transcriptasa inversa del vih-1 correlacionadas con una resistencia fenotipica a farmacos. |
| EP1326640A4 (en) * | 2000-09-15 | 2004-12-15 | Virologic Inc | NON-NUCLEOSIDIC REVERSE-TRANSCRIPTASE INHIBITOR AS ANTIRETROVIRAL THERAPY |
| EP1356082A2 (en) | 2000-10-20 | 2003-10-29 | Virco Bvba | Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
| JP4264256B2 (ja) * | 2000-10-20 | 2009-05-13 | ビルコ・ビーブイビーエイ | 治療に対する耐性を予測するための生物学的カット−オフ値の確立 |
| US7247439B1 (en) | 2001-06-04 | 2007-07-24 | Monogram Biosciences, Inc. | Method of evaluating a patient antibody response to envelope proteins of a virus |
| US7097970B2 (en) | 2001-06-04 | 2006-08-29 | Monogram Biosciences, Inc. | Methods of evaluating viral entry inhibitors using patient derived envelope protein constructs |
| WO2003040390A2 (en) | 2001-11-08 | 2003-05-15 | Tibotec Pharmaceuticals Ltd. | Protease assay for therapeutic drug monitoring |
| EP1520247B1 (en) | 2002-07-01 | 2009-05-27 | Tibotec Pharmaceuticals Ltd. | Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance |
| DE60321466D1 (de) | 2002-07-01 | 2008-07-17 | Tibotec Pharm Ltd | Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase |
| DE20218008U1 (de) | 2002-11-21 | 2003-03-06 | FESTO AG & Co., 73734 Esslingen | Anordnung von mehreren Handhabungsvorrichtungen |
| US8603736B2 (en) | 2004-06-07 | 2013-12-10 | Monogram Biosciences, Inc. | Compositions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays |
| US8178291B2 (en) | 2005-02-18 | 2012-05-15 | Monogram Biosciences, Inc. | Methods and compositions for determining hypersusceptibility of HIV-1 to non-nucleoside reverse transcriptase inhibitors |
| EP2522757A1 (en) | 2005-02-18 | 2012-11-14 | Monogram BioSciences, Inc. | Methods and compositions for determining anti-HIV drug susceptibility and replication capacity of HIV |
| CA2609910A1 (en) | 2005-05-27 | 2006-12-07 | Monogram Biosciences, Inc. | Methods and compositions for determining resistance of hiv-1 to protease inhibitors |
| WO2006133267A2 (en) | 2005-06-06 | 2006-12-14 | Monogram Biosciences, Inc. | Methods and compositions for determining altered susceptibility of hiv-1 to anti-hiv drugs |
| WO2006133266A2 (en) | 2005-06-06 | 2006-12-14 | Monogram Biosciences, Inc. | Methods for determining resistance or susceptibility to hiv entry inhibitors |
| WO2007146336A2 (en) | 2006-06-13 | 2007-12-21 | Monogram Biosciences, Inc. | Molecular determinants associated with enhanced ability to enter cells expressing cxcr4 |
| EP2126137B1 (en) | 2007-01-23 | 2017-06-07 | Janssen Pharmaceutica NV | Method for designing a drug regime for hiv-infected patients |
| WO2008106115A2 (en) | 2007-02-26 | 2008-09-04 | Monogram Biosciences, Inc. | Compositions and methods for determining whether a subject would benefit from co-receptor inhibitor therapy |
| JPWO2018030534A1 (ja) * | 2016-08-10 | 2019-06-13 | 国立研究開発法人理化学研究所 | Ｂ型肝炎治療用組成物、及びｂ型肝炎ウイルスの複製活性の評価方法 |
| RU2646472C1 (ru) * | 2016-10-07 | 2018-03-05 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный медицинский университет имени академика Е.А. Вагнера" Министерства здравоохранения Российской Федерации | Способ оценки эффективности терапии инфекции вызванной вирусом герпеса человека 6 типа у детей |
| CN110382009A (zh) * | 2016-12-29 | 2019-10-25 | 富荣吉有限责任公司 | Retro-HBV和Lenti-HBV的混合载体及构建体 |
| CN109722465B (zh) * | 2019-01-07 | 2022-02-01 | 福建省疾病预防控制中心(福建省健康教育促进中心、福建省卫生检验检测中心) | 一种hiv耐药检测载体和构建方法 |
| CN113832169B (zh) * | 2020-06-24 | 2025-10-14 | 厦门大学 | 靶向HBV cccDNA的药物筛选模型及方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0291893A1 (en) * | 1987-05-19 | 1988-11-23 | The Du Pont Merck Pharmaceutical Company | Stable human cell lines expressing an indicator gene product under virus-specific genetic controls |
| ATE118247T1 (de) * | 1988-09-27 | 1995-02-15 | Dana Farber Cancer Inst Inc | Vektor, der ein replikationskompetentes hiv-i- provirus und ein heterologes gen enthält. |
| HU209835B (en) * | 1988-12-07 | 1994-11-28 | Univ Osaka Res Found | Method for producing of retrovirus protease, reverse transcriptase and integrase |
| ATE161041T1 (de) * | 1989-08-25 | 1997-12-15 | Chiron Corp | Verfahren zur hcv-züchtung in zell-linien aus b- oder t-lymphozyten |
| GB8923123D0 (en) * | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| FR2700169B1 (fr) * | 1993-01-04 | 1995-03-24 | Transgene Sa | Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine. |
| US5645982A (en) * | 1993-08-19 | 1997-07-08 | Systemix, Inc. | Method for screening potential therapeutically effective antiviral agents |
| WO1995022622A1 (en) * | 1994-02-18 | 1995-08-24 | University Of Washington | Methods and compositions for screening for anti-aids drugs |
| US5733543A (en) * | 1994-04-29 | 1998-03-31 | Nabel; Gary J. | Introduction of HIV-protective genes into cells by particle-mediated gene transfer |
| DE69535669T2 (de) * | 1994-05-09 | 2008-12-04 | Oxford Biomedica (Uk) Ltd. | Retrovirale vektoren mit verminderter rekombinationsrate |
| US5837464A (en) * | 1996-01-29 | 1998-11-17 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
| CA2298102A1 (en) * | 1997-07-30 | 1999-02-11 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
-
1997
- 1997-01-29 EP EP97907549A patent/EP0852626B1/en not_active Expired - Lifetime
- 1997-01-29 EA EA199800669A patent/EA005426B1/ru not_active IP Right Cessation
- 1997-01-29 DE DE69711584T patent/DE69711584T2/de not_active Expired - Lifetime
- 1997-01-29 AP APAP/P/1998/001360A patent/AP9801360A0/en unknown
- 1997-01-29 CN CNB971929327A patent/CN1263867C/zh not_active Expired - Fee Related
- 1997-01-29 EP EP01117002A patent/EP1170380B1/en not_active Expired - Lifetime
- 1997-01-29 AT AT01117002T patent/ATE447621T1/de not_active IP Right Cessation
- 1997-01-29 KR KR1019980705851A patent/KR100537153B1/ko not_active Expired - Fee Related
- 1997-01-29 WO PCT/US1997/001609 patent/WO1997027319A1/en not_active Ceased
- 1997-01-29 NZ NZ331376A patent/NZ331376A/xx not_active IP Right Cessation
- 1997-01-29 JP JP52712397A patent/JP4183749B2/ja not_active Expired - Fee Related
- 1997-01-29 DE DE69739645T patent/DE69739645D1/de not_active Expired - Lifetime
- 1997-01-29 PL PL97328068A patent/PL328068A1/xx not_active IP Right Cessation
- 1997-01-29 CA CA002216126A patent/CA2216126C/en not_active Expired - Lifetime
- 1997-01-29 RO RO98-01216A patent/RO118887B1/ro unknown
- 1997-01-29 AU AU19528/97A patent/AU732255B2/en not_active Ceased
- 1997-01-29 ES ES97907549T patent/ES2175355T3/es not_active Expired - Lifetime
- 1997-01-29 HU HU9900388A patent/HUP9900388A3/hu unknown
- 1997-01-29 IL IL125464A patent/IL125464A/en not_active IP Right Cessation
-
1998
- 1998-07-24 NO NO983421A patent/NO983421L/no unknown